Today, CDC announced the release of more than 77,000 additional doses of Beyfortus(TM) (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease.
WordPress database error: [Table 'acdlpb3_wp339.wpe5_wpsecure_login' doesn't exist]SHOW COLUMNS FROM wpe5_wpsecure_login LIKE "country"
WordPress database error: [Table 'acdlpb3_wp339.wpe5_wpsecure_login' doesn't exist]ALTER TABLE wpe5_wpsecure_login ADD country VARCHAR(150)
WordPress database error: [Table 'acdlpb3_wp339.wpe5_wpsecure_login' doesn't exist]ALTER TABLE wpe5_wpsecure_login ADD city VARCHAR(100)
Today, CDC announced the release of more than 77,000 additional doses of Beyfortus(TM) (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease.